Reversible cardiomyopathy following treatment with amphotericin B and flucytosine.
Johnson
Rena E
RE
Campbell-Bright
Stacy
S
Raasch
Ralph H
RH
Rodgers
Jo E
JE
Rosenberg
Beth S
BS
D000666:Amphotericin B / Q000009:adverse effects* / Q000627:therapeutic use; D000935:Antifungal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000503:physiopathology; D003453:Cryptococcosis / Q000150:complications / Q000188:drug therapy; D004337:Drug Carriers; D004562:Electrocardiography; D005260:Female; D005437:Flucytosine / Q000009:adverse effects* / Q000627:therapeutic use; D006321:Heart / Q000000981:diagnostic imaging; D006334:Heart Function Tests; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008081:Liposomes; D008875:Middle Aged; D011877:Radionuclide Imaging
D000935:Antifungal Agents; D004337:Drug Carriers; D008081:Liposomes; D000666:Amphotericin B; D005437:Flucytosine